By: Emily Estrada
Clinical Summary: Design/Population: The phase 3 ARTEMIS-011 trial randomized patients aged 12 years and older with relapsed or refractory
Emily Estrada is a journalist at various esteemed publications including Endocrinology Advisor, Pulmonology Advisor, and the Los Angeles Times. She specializes in medicine and healthcare, covering a range of topics such as oncology, immunotherapy, and mental health care, with a focus on diagnostics and medical specialties. Her work has been featured in multiple outlets, highlighting her expertise across diverse areas of health and medicine.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
This information evolves through artificial intelligence and human feedback. Improve this profile .